Volume | 2,959,300 |
|
|||||
News | (1) | ||||||
Day High | 2.04 | Low High |
|||||
Day Low | 1.80 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ATAI Life Sciences NV | ATAI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.805 | 1.80 | 2.04 | 1.97 | 1.79 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,211 | 2,959,300 | $ 1.95 | $ 5,772,392 | - | 1.025 - 2.39 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:43:54 | formt | 435 | $ 1.92 | USD |
ATAI Life Sciences NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
327.04M | 166.01M | - | 233k | -152.39M | -0.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ATAI Life Sciences NV News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATAI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.72 | 2.04 | 1.60 | 1.70 | 1,076,025 | 0.20 | 11.63% |
1 Month | 2.00 | 2.315 | 1.58 | 1.91 | 1,582,903 | -0.08 | -4.00% |
3 Months | 1.60 | 2.315 | 1.51 | 1.89 | 1,472,602 | 0.32 | 20.00% |
6 Months | 1.34 | 2.315 | 1.025 | 1.65 | 1,124,899 | 0.58 | 43.28% |
1 Year | 1.40 | 2.39 | 1.025 | 1.73 | 1,045,936 | 0.52 | 37.14% |
3 Years | 21.00 | 22.91 | 1.025 | 4.07 | 936,296 | -19.08 | -90.86% |
5 Years | 1.03 | 22.91 | 0.98 | 3.85 | 959,885 | 0.89 | 86.41% |
ATAI Life Sciences NV Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |